Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
TherapeuticsMD Announces Closing of its Underwritten Public Offering of Common Stock
-
TherapeuticsMD (TXMD) Prices $110M Share Common Offering
-
TherapeuticsMD Announces Pricing of $110 Million Public Offering of Common Stock
-
TherapeuticsMD (TXMD) Announces Underwritten Public Offering of its Common Stock
-
TherapeuticsMD Announces Underwritten Public Offering of its Common Stock
-
TherapeuticsMD Announces Closing of its Underwritten Public Offering of Common Stock
-
TherapeuticsMD (TXMD) Prices $30 Million Public Offering of Common Stock
-
TherapeuticsMD Announces Pricing of $30 Million Public Offering of Common Stock
-
TherapeuticsMD (TXMD) Announces Underwritten Public Offering of its Common Stock
-
TherapeuticsMD Announces Underwritten Public Offering of its Common Stock
-
TherapeuticsMD (TXMD) Slides Show Annovera Soft Launch Expected Next Week - Cantor Fitzgerald
-
TherapeuticsMD (TXMD) Should Benefit From NuvaRing Delay - Cantor Fitzgerald
-
TherapeuticsMD (TXMD) PT Lowered to $13 at Cantor Fitzgerald
-
TherapeuticsMD Announces Closing of its Underwritten Public Offering and Concurrent Registered Direct Offering of Common Stock
-
TherapeuticsMD (TXMD) Prices Combined $65M Common Share Offering and $20M Registered Direct Offering by Investor at $5.10/Sh
-
TherapeuticsMD Announces Pricing of Its Underwritten Public Offering and Concurrent Registered Direct Offering for Aggregate Gross Proceeds of $85 Million
-
TherapeuticsMD (TXMD) Announces $65M Underwritten Public Offering and Concurrent $20M Registered Direct Offering
-
TherapeuticsMD Announces Proposed $65 Million Underwritten Public Offering and Concurrent $20 Million Registered Direct Offering of Common Stock
-
TherapeuticsMD (TXMD) PT Lowered to $26 at Cantor Fitzgerald
-
TherapeuticsMD (TXMD) PT Lowered to $28 at Cantor Fitzgerald
-
TherapeuticsMD (TXMD) Launches 12.4M Common Stock Offering
-
TherapeuticsMD Announces Public Offering of 12.4 Million Shares of Common Stock
-
TherapeuticsMD (TXMD) Gains as Analysts Cover Call from WHI-OS Co-Author
-
TherapeuticsMD to Present at Two Upcoming Investor Conferences
-
TherapeuticsMD (TXMD): FDA Letter Implies PDUFA Date May Slide - Cantor
-
Cantor Fitzgerald Reiterates Overweight Rating and $34 PT on TherapeuticsMD (TXMD); 'Compelling TX-001 Data' Continues
-
TherapeuticsMD (TXMD): Investor Day Recap - Cantor
-
Pre-Open Stock Movers 12/16: (JBL) (HZNP) (TXMD) Higher; (AGIO) (VCEL) (FNSR) Lower (more...)
-
Cantor Fitzgerald Starts TherapeuticsMD (TXMD) at Overweight
-
Pre-Open Stock Movers 1/24: (BDSI) (OTEX) (JNPR) Higher; (ATOS) (PTCT) (ISRG) Lower (more...)

